PAUL DAVIS: Open Payments
NPI 1386637221 · WHITE HALL, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$399 in 21 payments from 9 companies in 2025. Trend: 2023 $823 · 2024 $317 · 2025 $399
Food & beverage: $399
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $109 |
| ABBVIE INC. | 4 | $77 |
| Novo Nordisk Inc | 3 | $53 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Lundbeck LLC | 2 | $38 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Amgen Inc. | 1 | $19 |
| AngioDynamics, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, TRELEGY ELLIPTA, REXULTI, UBRELVY, GARDASIL 9, OTEZLA, AURYON LASER SYSTEM 100-120 VAC.
Industry payments across AR — which companies pay providers there.
